{"entity":{"id":"nct07824960","kind":"trial","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","aka":["Panc 004"],"tldr":"A phase 1/2 trial of avutometinib + defactinib in pancreatic cancer, run by University of Virginia, not yet recruiting.","summary":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma is a phase 1/2, interventional study registered as NCT07824960 by University of Virginia, with a registry enrolment figure of 31 participants, started 2026-10-01 and due to reach its primary completion in 2029-04. Interventions recorded: Avutometinib (VS-6766) + Defactinib (VS-6063). Conditions listed: Pancreatic Cancer; PDAC - Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Carcinoma; Locally Advanced Pancreatic Cancer. Primary outcome: Dose limiting toxicities (DLTs) - Part A; Objective response (OR) - Part B. Pancreatic eligibility wording from the registry: \"Adenocarcinoma of the pancreas, confirmed by histology or cytology\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07824960","url":"https://clinicaltrials.gov/study/NCT07824960"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac","locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["avutometinib-defactinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07824960","phase":"1/2","setting":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: A Phase IB/II Safety and Efficacy Study","sponsor":"University of Virginia","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07824960/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"drug":[{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}